New inhaled drug for lung disease takes first step in healthy people
NCT ID NCT07528703
First seen Apr 25, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This early-stage study tests a new inhaled drug called RC010 in 42 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood. This is a first step to see if the drug can be tested in patients with IPF.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.